Albion Technology & General VCT PLC
Albion KAY VCT has now merged into Albion Technology & General VCT. To access all the details click below
Key Highlights
Dividends paid since launch:
132.85p
NAV* at 31 March 2025:
Ordinary shares
71.68p
Total Return:
Ordinary shares
204.53p
Last dividend paid to shareholders:
30/06/2025
1.83p
*Where applicable, Net Asset Value is reduced by dividend declared.
The London Stock Exchange code for the VCT is AATG
Performance Data
The diagram above shows the one year, three year, five year and ten year total return to shareholders. This return comprises dividends paid and the change in net asset value over the relevant periods to 31 March 2025.
Net asset value per share and total shareholder value
The chart above illustrates the movement in net asset value per share plus cumulative dividends paid in the past ten years to 31 March 2025.
Percentage movement in shareholder value in the year
| 2021 | 2022 | 2023 | 2024 | March 2025 |
|---|---|---|---|---|
| 21.6% | (4.6%) | 3.8% | 6.6% | 0.6% |
The figures in the table above represent the percentage movement in shareholder value on opening NAV over the past five years. The Company has delivered an average increase in shareholder value on opening NAV of 5.6% per annum over the past five years.
Financials
Annual Report
Half-yearly Financial Report
Other
- AATG AGM Proxy Voting 17 June 2025
- AATG Interim Management Statement to 31 March 2025
- Financial Summary for Previous Funds - AATG, C share, AAIG and KAY Total Shareholder Value to 31 March 2025
- AATG Notice of Resolutions 11 December 2024
- AATG GM Proxy Voting 11 December 2024
- AATG Interim Management Statement to 30 September 2024
- Portfolio update - 2 July 2024
AGM
The AGM was held virtually on 17 June 2025.
The AGM recording is available to watch on-demand.
2025 AGM Recording
2025 Manager Presentation
Board of Directors
Clive Richardson
Chairman
Clive Richardson
Chairman
Clive Richardson, (appointed 1 June 2022), Chairman, has extensive experience across a range of private and public international healthcare and technology focused f irms from start-ups to mid-cap companies. He was Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting, a leading global strategy firm. He has held non-executive director roles and served as an executive board member on CIS Healthcare Limited and Clinisys Group Limited, both decision support healthcare software companies. He has served as CEO for Akari Therapeutics PLC, a NASDAQ listed biotechnology company and is currently CEO of con-join-AI, a healthcare technology company.
David Benda
Director
David Benda
Director
David Benda, (appointed 26 June 2023) has extensive corporate banking experience working with investment companies providing advice on fundraising, reorganisations and restructurings. He qualified as a chartered accountant with Coopers & Lybrand in London in 1994 and whilst working for them, he took up secondment in both the New York and Prague offices until his departure in 1997. Since then, David has worked in various corporate broking roles, including for HSBC James Capel and Winterflood Securities where he focused on investment companies. David was until recently a Managing Director at Deutsche Numis where he headed up the corporate side of the listed fund team and co-headed the team overall.
Simon Thorpe
Director
Simon Thorpe
Director
Simon Thorpe, (appointed 19 December 2024), is a qualified Chartered Accountant and former chairman and director of Cambridge Angels with substantial experience of analysing and investing in early-stage public and private companies in the technology and technology enabled healthcare sectors. His previous roles include Chief Operating Officer for European Equity Research and UBS Global Equity Research. He has had over 20 years experience as a public markets equity research analyst and since then over 15 years experience as an angel investor investing in more than 60 early stage UK private companies. He sits on a number of Boards as a Non-Executive Director including Manchester University’s Technology Transfer Office, the Innovation Factory and two private software companies.
Swarupa Pathakji
Director
Swarupa Pathakji
Director
Swarupa Pathakji, (appointed 19 December 2024), has considerable experience in private equity investment, strategic development, exits and valuations. She qualified as a chartered accountant at Deloitte before spending time in mergers and acquisitions at Merrill Lynch. She moved to Duke Street, a mid-market Private Equity firm, in 2007 and has served as a non-executive director on the boards of a number of companies across multiple sectors. She is currently a non-executive director of Motorpoint Group plc.
Portfolio highlights
Quantexa
Software
Proveca
Healthcare
Oviva
Healthcare
Elliptic
Software
Treefera
Software
Chonais River Hydro Ltd
Infrastructure
Dividends
We operate a variable dividend policy which targets an annual dividend yield of around 5% of the prevailing net asset value, paid bi-annually.
The Albion VCTs operate Dividend Re-investment Schemes. Investors who would prefer a capital growth option can re-invest their dividends to obtain more shares in the VCTs.
Any amounts reinvested are eligible for income tax relief of 30%, subject to the investor’s tax position.
Investors wishing to take advantage of this opportunity should read the dividend reinvestment schemes T&C below.
Shareholders who are in the dividend reinvestment scheme but want to receive dividend as cash can amend their income option via Investor Centre.
Shareholders can also amend their income option by completing a Payment of Interest form, found below, and send directly to Computershare.
If the shareholder choses to amend their income option via the Payment of Interest form, Computershare will also require a written confirmation from the shareholder to be fully removed from the scheme
Corporate Governance
Inside Information Announcements
Management Engagement Committee terms of reference
Nomination Committee terms of reference
Remuneration Committee terms of reference
Audit and Risk Committee terms of reference
Report Archive
Additional Information
Dividend Reinvestment Scheme
Shareholders who want to receive dividend as cash and decide not to amend their income option via Investor Centre (the online portal) must complete a payment of interest form and send directly to Computershare.
If the shareholder is in the dividend reinvestment scheme, Computershare will also require a written confirmation from the shareholder to be fully removed from the scheme.
Contact
Computershare Investor Services PLC can be contacted at their Investor Centre on +44 (0)370 873 5860 (Calls are charged at no more than your current providers national call rate and calls may be recorded. Lines are open Monday – Friday, 8:30am – 5:30pm).
Alternatively you can visit their website www.computershare.com/uk.
